211 related articles for article (PubMed ID: 28260984)
1. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
Matsui T; Umetsu R; Kato Y; Hane Y; Sasaoka S; Motooka Y; Hatahira H; Abe J; Fukuda A; Naganuma M; Kinosada Y; Nakamura M
Int J Med Sci; 2017; 14(2):102-109. PubMed ID: 28260984
[TBL] [Abstract][Full Text] [Related]
2. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
[TBL] [Abstract][Full Text] [Related]
3. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
4. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
5. The Risk of Glioblastoma with TNF Inhibitors.
Guo M; Luo H; Samii A; Etminan M
Pharmacotherapy; 2016 Apr; 36(4):449-54. PubMed ID: 26931498
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis.
Benucci M; Saviola G; Baiardi P; Manfredi M; Sarzi-Puttini P; Atzeni F
Int J Immunopathol Pharmacol; 2011; 24(1):269-74. PubMed ID: 21496415
[TBL] [Abstract][Full Text] [Related]
7. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
[TBL] [Abstract][Full Text] [Related]
8. Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases.
Chen C; Borrego ME; Roberts MH; Raisch DW
Expert Opin Drug Saf; 2019 Aug; 18(8):733-744. PubMed ID: 31173698
[No Abstract] [Full Text] [Related]
9. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
10. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
11. A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
Cho SK; Sakai R; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Tanaka Y; Nakajima A; Yasuda S; Ihata A; Ezawa K; Won S; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Miyasaka N; Bae SC; Harigai M; ;
Mod Rheumatol; 2014 Jul; 24(4):572-9. PubMed ID: 24320747
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
13. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Drug Saf; 2013 May; 36(5):329-34. PubMed ID: 23580194
[TBL] [Abstract][Full Text] [Related]
14. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
[TBL] [Abstract][Full Text] [Related]
15. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
16. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
17. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
[TBL] [Abstract][Full Text] [Related]
18. First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Velthuis K; Jessurun NT; Nguyen TDM; Scholl J; Jansen JRG; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE
Expert Opin Drug Saf; 2023; 22(6):485-492. PubMed ID: 36683590
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
[TBL] [Abstract][Full Text] [Related]
20. Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016.
Ha D; Lee SE; Song I; Lim SJ; Shin JY
Clin Rheumatol; 2020 Feb; 39(2):347-355. PubMed ID: 31673980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
